CagriSema setback hits Novo Nordisk as trials disappoint
TL;DR
Novo Nordisk’s next‑gen weight‑loss drug CagriSema failed to meet its primary endpoint in a late‑stage trial, delivering 23% average weight loss over 84 weeks versus 25.5% for Eli Lilly’s tirzepatide, prompting a sharp stock drop and renewed investor skepticism. The company plans a higher‑dose study and continues pursuing approval based on earlier data, while analysts noted the result as a setback for its obesity‑drug ambitions.
Topics:business#business#cagrisema#clinical-trial-results#novo-nordisk#stock-decline#weight-loss-drug
- Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’ The Guardian
- Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial CNBC
- Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound The Wall Street Journal
- Novo Next-Generation Obesity Shot Falls Short of Lilly Rival Bloomberg.com
- Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters
Want the full story? Read the original reporting
Read on The Guardian